首页 > 最新文献

Clinical Advances in Hematology & Oncology最新文献

英文 中文
Management options for node-positive muscle-invasive bladder cancer. 结节阳性肌肉浸润性膀胱癌的治疗方案。
IF 1.1 Q4 ONCOLOGY
Clinical Advances in Hematology & Oncology
Pub Date : 2024-10-01
Hyma V Polimera, Priyanka Bhatia, Megan Wheelden, Stuthi Perimbeti, Joshua Warrick, Monika Joshi

Localized node-positive bladder cancer is characterized by a high degree of heterogeneity, leading to significant variability in overall survival outcomes among affected individuals. The absence of standardized treatment guidelines presents a critical challenge in managing these patients effectively. This comprehensive review article delves into the pathophysiology, clinical significance, and management of node-positive bladder cancer. It critically evaluates the current therapeutic landscape and explores emerging treatment strategies, including novel drugs currently undergoing clinical trials. By synthesizing the latest research findings, the review aims to provide valuable insights into the optimal management of node-positive urothelial cell carcinoma, ultimately contributing to improved patient outcomes and quality of life.

局部结节阳性膀胱癌具有高度的异质性，导致患者的总体生存结果存在显著差异。标准化治疗指南的缺失为有效管理这些患者带来了严峻挑战。这篇综合性综述文章深入探讨了结节阳性膀胱癌的病理生理学、临床意义和治疗方法。文章对当前的治疗现状进行了批判性评估，并探讨了新兴的治疗策略，包括目前正在进行临床试验的新型药物。通过综合最新的研究成果，该综述旨在为结节阳性尿路上皮细胞癌的最佳治疗提供有价值的见解，最终有助于改善患者的预后和生活质量。
{"title":"Management options for node-positive muscle-invasive bladder cancer.","authors":"Hyma V Polimera, Priyanka Bhatia, Megan Wheelden, Stuthi Perimbeti, Joshua Warrick, Monika Joshi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Localized node-positive bladder cancer is characterized by a high degree of heterogeneity, leading to significant variability in overall survival outcomes among affected individuals. The absence of standardized treatment guidelines presents a critical challenge in managing these patients effectively. This comprehensive review article delves into the pathophysiology, clinical significance, and management of node-positive bladder cancer. It critically evaluates the current therapeutic landscape and explores emerging treatment strategies, including novel drugs currently undergoing clinical trials. By synthesizing the latest research findings, the review aims to provide valuable insights into the optimal management of node-positive urothelial cell carcinoma, ultimately contributing to improved patient outcomes and quality of life.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 8","pages":"392-402"},"PeriodicalIF":1.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlights in metastatic prostate cancer from the European Society for Medical Oncology Congress 2024: commentary. 欧洲肿瘤内科学会 2024 年大会转移性前列腺癌亮点：评论。
IF 1.1 Q4 ONCOLOGY
Clinical Advances in Hematology & Oncology
Pub Date : 2024-10-01
Pedro C Barata
{"title":"Highlights in metastatic prostate cancer from the European Society for Medical Oncology Congress 2024: commentary.","authors":"Pedro C Barata","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 Suppl 6 8","pages":"7-17"},"PeriodicalIF":1.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can unresectable non-small cell lung cancer become resectable? 无法切除的非小细胞肺癌可以切除吗？
IF 1.1 Q4 ONCOLOGY
Clinical Advances in Hematology & Oncology
Pub Date : 2024-07-01
Jamie E Chaft
{"title":"Can unresectable non-small cell lung cancer become resectable?","authors":"Jamie E Chaft","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 6","pages":"261-262"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on CDK4/6 inhibitors in breast cancer. 乳腺癌 CDK4/6 抑制剂的最新进展。
IF 1.1 Q4 ONCOLOGY
Clinical Advances in Hematology & Oncology
Pub Date : 2024-07-01
Sara M Tolaney
{"title":"Update on CDK4/6 inhibitors in breast cancer.","authors":"Sara M Tolaney","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 6","pages":"298-300"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Q&A: Barriers to testing for NTRK fusions in metastatic lung and thyroid cancer. 问与答：检测转移性肺癌和甲状腺癌中 NTRK 融合的障碍。
IF 1.1 Q4 ONCOLOGY
Clinical Advances in Hematology & Oncology
Pub Date : 2024-07-01
David S Hong, Alexander Drilon, Lori J Wirth
{"title":"Q&A: Barriers to testing for NTRK fusions in metastatic lung and thyroid cancer.","authors":"David S Hong, Alexander Drilon, Lori J Wirth","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 Suppl 5 6","pages":"16"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of patients with NTRK fusion-positive lung cancer. NTRK 融合阳性肺癌患者的管理。
IF 1.1 Q4 ONCOLOGY
Clinical Advances in Hematology & Oncology
Pub Date : 2024-07-01
Alexander Drilon
{"title":"Management of patients with NTRK fusion-positive lung cancer.","authors":"Alexander Drilon","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 Suppl 5 6","pages":"5-9"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers. NTRK 抑制剂对 NTRK 融合阳性肺癌和甲状腺癌患者的疗效和安全性。
IF 1.1 Q4 ONCOLOGY
Clinical Advances in Hematology & Oncology
Pub Date : 2024-07-01
David S Hong, Alexander Drilon, Lori J Wirth

Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are implicated in various cancers, including those of the lung and thyroid. The prevalence of NTRK fusions is 0.1 to 0.3% in non-small cell lung cancer (NSCLC) and as high as 26% in pediatric papillary thyroid carcinoma. Detection methods include immunohistochemistry, fluorescence in situ hybridization, reverse transcription polymerase chain reaction, and next-generation sequencing. Management of NTRK fusion-positive lung cancer primarily involves targeted therapies, notably the tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib. Both agents demonstrate high response rates and durable disease control, particularly in metastatic adenocarcinoma of the lung. They are preferred as first-line treatments because of their efficacy over immunotherapy. Possible adverse events include dizziness, weight gain, neuropathy-like pain, and liver enzyme elevation. Larotrectinib and entrectinib also produce robust and durable responses in NTRK fusion-positive thyroid cancer that is refractory to radioactive iodine. Second-generation TRK inhibitors that have been designed to overcome acquired resistance are under investigation.

神经营养酪氨酸受体激酶（NTRK）基因融合与多种癌症有关，包括肺癌和甲状腺癌。NTRK基因融合在非小细胞肺癌（NSCLC）中的发病率为0.1%至0.3%，在小儿甲状腺乳头状癌中的发病率高达26%。检测方法包括免疫组化、荧光原位杂交、逆转录聚合酶链反应和新一代测序。NTRK融合阳性肺癌的治疗主要采用靶向疗法，特别是酪氨酸受体激酶（TRK）抑制剂拉罗替尼（larotrectinib）和恩替瑞尼（entrectinib）。这两种药物都具有高应答率和持久的疾病控制效果，尤其适用于转移性肺腺癌。由于它们的疗效优于免疫疗法，因此是一线治疗的首选药物。可能出现的不良反应包括头晕、体重增加、神经病变样疼痛和肝酶升高。拉罗替尼（Larotrectinib）和恩替瑞尼（entrectinib）也能对放射性碘难治的NTRK融合阳性甲状腺癌产生强有力的持久反应。目前正在研究旨在克服获得性耐药性的第二代 TRK 抑制剂。
{"title":"Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers.","authors":"David S Hong, Alexander Drilon, Lori J Wirth","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are implicated in various cancers, including those of the lung and thyroid. The prevalence of NTRK fusions is 0.1 to 0.3% in non-small cell lung cancer (NSCLC) and as high as 26% in pediatric papillary thyroid carcinoma. Detection methods include immunohistochemistry, fluorescence in situ hybridization, reverse transcription polymerase chain reaction, and next-generation sequencing. Management of NTRK fusion-positive lung cancer primarily involves targeted therapies, notably the tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib. Both agents demonstrate high response rates and durable disease control, particularly in metastatic adenocarcinoma of the lung. They are preferred as first-line treatments because of their efficacy over immunotherapy. Possible adverse events include dizziness, weight gain, neuropathy-like pain, and liver enzyme elevation. Larotrectinib and entrectinib also produce robust and durable responses in NTRK fusion-positive thyroid cancer that is refractory to radioactive iodine. Second-generation TRK inhibitors that have been designed to overcome acquired resistance are under investigation.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 Suppl 5 6","pages":"1-20"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia. 批准在慢性淋巴细胞白血病中使用 lisocabtagene maraleucel。
IF 1.1 Q4 ONCOLOGY
Clinical Advances in Hematology & Oncology
Pub Date : 2024-07-01
William G Wierda
{"title":"The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia.","authors":"William G Wierda","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 6","pages":"291-293"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of patients with NTRK fusion-positive thyroid cancer. 对NTRK融合阳性甲状腺癌患者的治疗。
IF 1.1 Q4 ONCOLOGY
Clinical Advances in Hematology & Oncology
Pub Date : 2024-07-01
Lori J Wirth
{"title":"Management of patients with NTRK fusion-positive thyroid cancer.","authors":"Lori J Wirth","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 Suppl 5 6","pages":"9-15"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapies. 子宫浆液性癌和子宫癌肉瘤：分子特征、临床进展和新兴疗法。
IF 1.1 Q4 ONCOLOGY
Clinical Advances in Hematology & Oncology
Pub Date : 2024-07-01
Elizabeth K Lee, Joyce F Liu

Endometrial cancer, including high-grade subtypes, has a rising incidence and mortality. Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) make up a small but increasing proportion of endometrial cancer cases and account for a significant portion of endometrial cancer mortality. Despite being molecularly and clinically distinct, both USC and UCS have a poor prognosis. Thus far, there have been few therapeutic strategies directed at these endometrial cancer subtypes. This review summarizes the genomic and molecular features of USC and UCS, clinical advances in the treatment of primary advanced and recurrent endometrial cancer, and novel molecularly-driven treatment strategies.

子宫内膜癌（包括高级别亚型）的发病率和死亡率不断上升。子宫浆液性癌（USC）和子宫癌肉瘤（UCS）在子宫内膜癌病例中所占比例虽小，但却在不断增加，并在子宫内膜癌死亡率中占了相当大的比例。尽管在分子和临床上有所不同，但 USC 和 UCS 的预后都很差。迄今为止，针对这些子宫内膜癌亚型的治疗策略还很少。本综述总结了 USC 和 UCS 的基因组和分子特征、治疗原发性晚期和复发性子宫内膜癌的临床进展以及分子驱动的新型治疗策略。
{"title":"Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapies.","authors":"Elizabeth K Lee, Joyce F Liu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Endometrial cancer, including high-grade subtypes, has a rising incidence and mortality. Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) make up a small but increasing proportion of endometrial cancer cases and account for a significant portion of endometrial cancer mortality. Despite being molecularly and clinically distinct, both USC and UCS have a poor prognosis. Thus far, there have been few therapeutic strategies directed at these endometrial cancer subtypes. This review summarizes the genomic and molecular features of USC and UCS, clinical advances in the treatment of primary advanced and recurrent endometrial cancer, and novel molecularly-driven treatment strategies.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 6","pages":"301-310"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Clinical Advances in Hematology & Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1